Selective VDRA vitamin D analogs such as paricalcitol (19‐nor‐1,25‐dihydroxy vitamin D2) and maxacalcitol (22‐oxa‐1,25‐dihydroxy vitamin D3) can reduce PTH levels better than calciferol without increasing the serum calcium concentration; however, it can cause hypercalcemia in some SHP patients. This evidence concerns the gene PTH and hypercalcemia disease.